In this study, the mutation status of EGFR and K-RAS as well as the EGFR and p-EGFR expressions on the primary tumours and the corresponding metastatic lesions were evaluated in 25 patients with advanced NSCLC. This evidence concerns the gene KRAS and neoplasm.